Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | G-631 |
Synonyms | |
Therapy Description |
G-631 inhibits Tankyrase 1 and 2 (TNK1, TNK2), resulting in decreased Wnt/Beta-catenin pathway signaling, but has little anti-tumor activity and leads to intestinal toxicity (PMID: 26692561). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
G-631 | Tankyrase Inhibitor 11 | G-631 inhibits Tankyrase 1 and 2 (TNK1, TNK2), resulting in decreased Wnt/Beta-catenin pathway signaling, but has little anti-tumor activity and leads to intestinal toxicity (PMID: 26692561). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
APC mutant | colorectal cancer | no benefit | G-631 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, G-631 inhibited Wnt pathway signaling in colorectal cancer cell line xenograft models harboring an APC mutation, but demonstrated little anti-tumor activity and led to intestinal toxicity (PMID: 26692561). | 26692561 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|